BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34184091)

  • 21. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
    Kawabata H; Suzuki H; Ohishi T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):59-66. PubMed ID: 35471051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors.
    Li G; Ohishi T; Kaneko MK; Takei J; Mizuno T; Kawada M; Saito M; Suzuki H; Kato Y
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody.
    Goto N; Suzuki H; Ohishi T; Harakawa A; Li G; Saito M; Takei J; Tanaka T; Asano T; Sano M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):67-73. PubMed ID: 35377239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
    Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
    Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
    Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
    J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers.
    Tanaka T; Ohishi T; Saito M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Feb; 41(1):32-38. PubMed ID: 35225665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.
    Nanamiya R; Ohishi T; Suzuki H; Mizuno T; Yoshikawa T; Asano T; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):27-33. PubMed ID: 36399552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.
    Maadi H; Nami B; Tong J; Li G; Wang Z
    BMC Cancer; 2018 Mar; 18(1):238. PubMed ID: 29490608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defucosylated Monoclonal Antibody (H
    Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H
    Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
    Kawabata H; Ohishi T; Suzuki H; Asano T; Kawada M; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Dec; 41(6):320-327. PubMed ID: 35483055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
    Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.